Synopsis
Synopsis
0
KDMF
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
2. Calipsol
3. Calypsol
4. Ci 581
5. Ci-581
6. Ci581
7. Kalipsol
8. Ketalar
9. Ketamine
10. Ketanest
11. Ketaset
1. 1867-66-9
2. Vetalar
3. Ketaset
4. Ketalar
5. Ketamine Hcl
6. Ketanest
7. Ketolar
8. 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
9. Cl 369
10. Cn-52,372-2
11. (+-)-ketamine Hydrochloride
12. Ci-581
13. Ketamine Hydrochloride Ciii
14. Ketamine (as Hydrochloride)
15. O18yuo0i83
16. Calipsol
17. Kalipsol
18. Ketavet
19. (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
20. Cl-369
21. Dea No. 7285
22. Cn-523722
23. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one;hydrochloride
24. Cn-52372-2
25. Ketamine Chloride
26. Ketavet 100
27. Ketavet (veterinary)
28. Ci 581
29. Chebi:650657
30. Einecs 217-484-6
31. Unii-o18yuo0i83
32. Ketalar (tn)
33. Ketamini Hydrochloridum
34. Ketamine Hydrochloride [usan:usp:jan]
35. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride
36. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
37. Ec 217-484-6
38. Chembl1714
39. Schembl26999
40. Dtxsid4040137
41. Ketamine Hydrochloride [mi]
42. 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one Hydrochloride
43. Bcp25943
44. Ketamine Hydrochloride (jp17/usp)
45. Ketamine Hydrochloride [jan]
46. (+/-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanone Hydrochloride
47. Ketamine Hydrochloride [usan]
48. Nsc116131
49. (+/-)-ketamine Hydrochloride, Solid
50. Ketamine Hydrochloride [vandf]
51. Akos005287313
52. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+-)-
53. Ketamine Hydrochloride [mart.]
54. Ab02117
55. Ketamine Hydrochloride [who-dd]
56. Ketamine Hydrochloride [who-ip]
57. Nsc-116131
58. Ketamine Hydrochloride [green Book]
59. Db-044614
60. Db-048467
61. Ketamine Hydrochloride [ep Impurity]
62. Ketamine Hydrochloride [orange Book]
63. Ketamine Hydrochloride [ep Monograph]
64. Ketamine Hydrochloride Ciii [usp-rs]
65. Ketamine Hydrochloride [usp Monograph]
66. Ketamini Hydrochloridum [who-ip Latin]
67. C07843
68. D00711
69. 867k669
70. A813079
71. Q-201266
72. Q27105184
73. Ketamine Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
74. 2-(2-chlorophenyl)-2-(methylamino)-1-cyclohexanone Hydrochloride
75. Ketamine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
76. Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, Hydrochloride (1:1)
77. Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, Hydrochloride, (+/-)-
78. Ketamine (+-)-2-(o-chlorophenyl)-2-(methylamino)cyclohexanonehydrochloride
79. Ketamine Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 274.18 g/mol |
---|---|
Molecular Formula | C13H17Cl2NO |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 2 |
Exact Mass | 273.0687196 g/mol |
Monoisotopic Mass | 273.0687196 g/mol |
Topological Polar Surface Area | 29.1 Ų |
Heavy Atom Count | 17 |
Formal Charge | 0 |
Complexity | 269 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
2 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
3 of 4 | |
---|---|
Drug Name | Ketalar |
Drug Label | Ketalar is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection in concentrat... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Par Sterile Products |
4 of 4 | |
---|---|
Drug Name | Ketamine hydrochloride |
PubMed Health | Ketamine (Injection) |
Drug Label | Ketamine hydrochloride is a nonbarbiturate anesthetic chemically designated dl 2-(0-chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. It is formulated as a slightly acid (pH 3.5-5.5) sterile solution for intravenous or intramuscular injectio... |
Active Ingredient | Ketamine hydrochloride |
Dosage Form | Injectable |
Route | Injection |
Strength | eq 10mg base/ml; eq 50mg base/ml; eq 100mg base/ml |
Market Status | Prescription |
Company | Hospira; Mylan Institutional; Eurohlth Intl |
Anesthetics, Dissociative
Intravenous anesthetics that induce a state of sedation, immobility, amnesia, and marked analgesia. Subjects may experience a strong feeling of dissociation from the environment. The condition produced is similar to NEUROLEPTANALGESIA, but is brought about by the administration of a single drug. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed) (See all compounds classified as Anesthetics, Dissociative.)
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
Excitatory Amino Acid Antagonists
Drugs that bind to but do not activate excitatory amino acid receptors, thereby blocking the actions of agonists. (See all compounds classified as Excitatory Amino Acid Antagonists.)
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-11-05
Pay. Date : 2019-10-28
DMF Number : 7686
Submission : 1988-09-22
Status : Active
Type : II
Certificate Number : CEP 2005-281 - Rev 02
Issue Date : 2024-03-11
Type : Chemical
Substance Number : 1020
Status : Valid
Registration Number : 218MF10980
Registrant's Address : Raiffeisenstrasse 4, D-77933 Lahr Germany
Initial Date of Registration : 2006-12-01
Latest Date of Registration : --
NDC Package Code : 49169-1041
Start Marketing Date : 2024-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : CA |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-12-22
Pay. Date : 2022-12-20
DMF Number : 27921
Submission : 2014-01-15
Status : Active
Type : II
Certificate Number : CEP 2016-194 - Rev 01
Issue Date : 2024-05-07
Type : Chemical
Substance Number : 1020
Status : Valid
Date of Issue : 2022-06-29
Valid Till : 2025-07-02
Written Confirmation Number : WC-0218
Address of the Firm :
NDC Package Code : 61281-8000
Start Marketing Date : 2013-07-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF, AU, CA |
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-04-06
Pay. Date : 2015-04-16
DMF Number : 29094
Submission : 2015-04-14
Status : Active
Type : II
Certificate Number : R1-CEP 2015-037 - Rev 01
Issue Date : 2023-02-08
Type : Chemical
Substance Number : 1020
Status : Valid
NDC Package Code : 10920-597
Start Marketing Date : 2013-12-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-06-09
Pay. Date : 2021-04-29
DMF Number : 35385
Submission : 2020-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37014
Submission : 2022-03-29
Status : Active
Type : II
Certificate Number : CEP 2022-157 - Rev 00
Issue Date : 2024-03-04
Type : Chemical
Substance Number : 1020
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19082
Submission : 2005-12-16
Status : Active
Type : II
Certificate Number : R1-CEP 1998-125 - Rev 04
Issue Date : 2012-02-09
Type : Chemical
Substance Number : 1020
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5462
Submission : 1984-07-17
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22256
Submission : 2008-11-28
Status : Inactive
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2019-11-05
Pay. Date : 2019-10-28
DMF Number : 7686
Submission : 1988-09-22
Status : Active
Type : II
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
GDUFA
DMF Review : Complete
Rev. Date : 2022-12-22
Pay. Date : 2022-12-20
DMF Number : 27921
Submission : 2014-01-15
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-04-06
Pay. Date : 2015-04-16
DMF Number : 29094
Submission : 2015-04-14
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19082
Submission : 2005-12-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 5462
Submission : 1984-07-17
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2021-06-09
Pay. Date : 2021-04-29
DMF Number : 35385
Submission : 2020-12-30
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22256
Submission : 2008-11-28
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37014
Submission : 2022-03-29
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Certificate Number : CEP 2005-281 - Rev 02
Status : Valid
Issue Date : 2024-03-11
Type : Chemical
Substance Number : 1020
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Certificate Number : CEP 2016-194 - Rev 01
Status : Valid
Issue Date : 2024-05-07
Type : Chemical
Substance Number : 1020
Certificate Number : R1-CEP 2015-037 - Rev 01
Status : Valid
Issue Date : 2023-02-08
Type : Chemical
Substance Number : 1020
Certificate Number : R1-CEP 1998-125 - Rev 04
Status : Valid
Issue Date : 2012-02-09
Type : Chemical
Substance Number : 1020
Certificate Number : R1-CEP 2007-362 - Rev 01
Status : Valid
Issue Date : 2014-11-27
Type : Chemical
Substance Number : 1020
Certificate Number : CEP 2022-157 - Rev 00
Status : Valid
Issue Date : 2024-03-04
Type : Chemical
Substance Number : 1020
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Registration Number : 218MF10980
Registrant's Address : Raiffeisenstrasse 4, D-77933 Lahr Germany
Initial Date of Registration : 2006-12-01
Latest Date of Registration : 2021-12-09
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
Ketamine Hydrochloride (BP/EP/USP)
Date of Issue : 2022-06-29
Valid Till : 2025-07-02
Written Confirmation Number : WC-0218
Address of the Firm : A-5/2, Late Parshuram Industrial Area, MIDC, Tal-Khed, Dist. Ratnagiri-415 722, ...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 54382-128
Start Marketing Date : 1989-08-02
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 54382-114
Start Marketing Date : 1989-02-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
NDC Package Code : 49169-1041
Start Marketing Date : 2024-01-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
NDC Package Code : 61281-8000
Start Marketing Date : 2013-07-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 10920-701
Start Marketing Date : 2022-01-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 73377-250
Start Marketing Date : 2023-09-20
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 76003-2673
Start Marketing Date : 2010-09-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 62991-1087
Start Marketing Date : 2009-06-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-1754
Start Marketing Date : 2015-03-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 51927-0292
Start Marketing Date : 2002-07-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
VMF Number : 5368
Submission : 1991-07-15
Status : Inactive
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Suanfarma founded in 1993, is a B2B life science partner committed to health & innovation by developing, manufacturing, & distributing high-quality APIs for the pharmaceutical indu...
Supriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.
About the Company : Supriya Lifescience Ltd. specializes in API manufacturing, focusing on therapeutic segments like antihistamines, anti-allergic drugs, vitamins, anaesthetics and anti-asthmatics. Su...
About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...
About the Company : Arevipharma GmbH is a modern manufacturer of active pharmaceutical ingredients and intermediates with more than 140 years of expertise. Our customers are generic and research-based...
About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...
About the Company : Maithri Drugs is one of India's fast-growing pharmaceutical companies. Maithri's strategic focus is on active pharma ingredients (APIs). The company is widely recognized for its ex...
About the Company : SB Pharma GmbH, with its headquarters in Cologne, is a leading company that has set itself the goal of offering pharmaceuticals, medical products and medical devices as well as a b...
About the Company : With over 85 years of experience, Uquifa provides comprehensive services supporting projects from proof of concept to commercial manufacturing. Uquifa’s business model is built o...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
R-107 Depression Study Results Published in Nature Medicine
Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.
Brand Name : R-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 25, 2024
Details:
R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance dosing.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107
Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...
Brand Name : R-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2023
Details:
R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: R-107
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2021
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Trial Data Suggests Major Breakthrough in Treatment Resistant Depression
Details : R-107 (extended-release oral dose of ketamine) act as a blocks the NMDA receptor and it is investigated for the treatment of treatment resistant depression.
Brand Name : R-107
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 15, 2021
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 26, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Announces Update On FDA New Drug Application for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Brand Name : Ketarx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 26, 2024
Details:
MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: MELT-300
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2024
Lead Product(s) : Midazolam,Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Melt Reports Positive Phase 3 Results for MELT-300 in Opioid-Free Cataract Sedation
Details : MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.
Brand Name : MELT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2024
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Announces Update On FDA New Drug Application for Ketamine
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Brand Name : Ketarx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 19, 2024
Details:
SP-26 is a ketamine HCl-based injectable dissolvable polymer implant beng investigated for the treatment of chronic pain and fibromyalgia.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Musculoskeletal Brand Name: SP-26
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Silo Pharma Achieves Positive Outcomes in SP-26 Ketamine Implant Testing
Details : SP-26 is a ketamine HCl-based injectable dissolvable polymer implant beng investigated for the treatment of chronic pain and fibromyalgia.
Brand Name : SP-26
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2024
Details:
Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketarx
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Receives FDA Response Letter for Ketamine Abbreviated Drug Application
Details : Ketarx (ketamine) is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Brand Name : Ketarx
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 23, 2024
Details:
MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.
Lead Product(s): Midazolam,Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: MELT-300
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2024
Lead Product(s) : Midazolam,Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Melt Doses Last Patient in Phase 3 Study For MELT-300 Sedation
Details : MELT-300, a non-intravenous, non-opioid tablet that blends fixed doses of midazolam and ketamine. This medication is designed for procedural sedation during cataract surgery.
Brand Name : MELT-300
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2024
Details:
Ketamine is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Brand Name: Ketamine-Generic
Study Phase: Phase II/ Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 04, 2024
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Announces Update on FDA New Drug Application for Ketamine
Details : Ketamine is a NMDA receptor antagonist, which is being evaluated as a potential treatment for mental health, and neurological disorders like parkinsons.
Brand Name : Ketamine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 04, 2024
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
13 Apr 2024
Reply
04 Jan 2024
Reply
08 Dec 2023
Reply
13 Nov 2020
Reply
21 Aug 2019
Reply
18 Jul 2019
Reply
13 Jun 2019
Reply
13 Oct 2018
Reply
09 Oct 2018
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?